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Abstract 
Background: There is a substantial and unmet clinical need for pharmacological treatment of cannabis 
use disorders. Cannabidiol (CBD) could offer a novel treatment but it is unclear which doses might be 
effective or safe. 
Methods: Participants meeting DSM-5 cannabis use disorder criteria were allocated to four-week 
treatment with oral CBD at 200mg, 400mg, 800mg or placebo during a cessation attempt using a 
double-blinded block randomisation sequence. All received a brief psychological intervention of 
motivational interviewing. An adaptive Bayesian dose-finding design was used to identify 
effective/ineffective doses at a priori interim and final analysis stages. The primary objective was to 
identify the Most Effective Dose (MED) of CBD for reducing cannabis use. The primary endpoint 
was lower urinary THC-COOH:creatinine concentrations and/or increased days per week abstinent 
from cannabis during treatment, evidenced by posterior probabilities exceeding Pr=0.9 for CBD 
versus placebo. All analyses were intention-to-treat. 
Outcomes: Participants were initially randomised to placebo, 200mg, 400mg and 800mg CBD (n=48; 
1:1:1:1). At interim analysis 200mg CBD was eliminated from the trial as an ineffective dose. 
Randomisation continued to 400mg CBD, 800mg CBD, and placebo (n=34; 1:1:1). At final analysis, 
both 400mg CBD and 800mg CBD exceeded primary endpoint criteria (Pr=0.9) for both primary 
outcomes: urinary THC-COOH:creatinine (Pr(400mg=MED │Data)=0.9995;  Pr(800mg=MED │Data)=0.9965), days 
per week abstinent from cannabis (Pr(400mg=MED │Data)=0.9966; Pr(800mg=MED │Data)=0.9247). Compared to 
placebo, 400mg CBD decreased THC-COOH:creatinine concentrations by -94.21 ng/ml (95% 
Interval Estimate= -161.83, -35.56) and increased abstinence from cannabis by 0.48 days per week 
(95% Interval Estimate=0.15, 0.82). Compared to placebo, 800mg CBD decreased THC-
COOH:creatinine concentrations by -72.02 ng/ml (95% Interval Estimate= -135.47, -19.52) and 
increased abstinence from cannabis by 0.27 days per week (95% Interval Estimate= -0.09, 0.64). CBD 
was well tolerated with no severe adverse events and 94% completed treatment. 
Interpretation: In the first randomised clinical trial of CBD for cannabis use disorder, 400mg and 
800mg CBD were safe and more effective than placebo at reducing cannabis use.  
Trial registration:  https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000361-36/GB 
Funding: Medical Research Council. 
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Research in context 
Evidence before the study: 
We searched the Cochrane database and peer-reviewed journal articles in Google Scholar using the 
terms ‘CBD’, ‘Cannabis’ and ‘Marijuana’ up to 12th March 2020. No language restrictions were 
imposed. A Cochrane review on pharmacotherapies for cannabis use disorders published in 2019 did 
not recommend any pharmacotherapies for reducing cannabis use in clinical settings. There were no 
randomised trials testing CBD as a treatment for cannabis use disorder. 
Added value of this study: 
This is the first randomised clinical trial of CBD for the treatment of cannabis use disorder. It used an 
adaptive Bayesian dose-finding design with doses ranging from 200mg to 800mg CBD to maximise 
trial efficiency and likelihood of success in identifying a potentially effective dose. 
Implications of all available evidence: 
At daily oral doses of 400mg or 800mg, CBD shows potential as a safe and effective treatment for 
reducing cannabis use in people with a cannabis use disorder, assessed by both biological and self-
report measures. 
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Introduction 
Cannabis is increasingly being legalised for medicinal and recreational use. The long-term 
effects of these policy reforms are unclear at present but may include substantial changes to 
the types of cannabis product sold and their availability to millions of people worldwide.1 
When considering the potential health effects of cannabis use, its largest contribution to the 
global burden of disease is the impact of cannabis use disorders, which affect an estimated 22 
million people worldwide – similar to the prevalence of opioid use disorders.2  
 
Delta-9-tetrahydrocannabinol (THC), a partial cannabinoid receptor agonist, is the primary 
cannabinoid in cannabis products and causes dose-dependent intoxicating and reinforcing 
effects.1 Studies in Europe3 and the USA4 reported a two-fold increase in THC concentrations 
in cannabis during the last decade. Use of higher THC products has been associated with a 
greater severity of cannabis use disorder5,6 and increases in the treated incidence of cannabis 
use disorders.7 In the past two decades, the proportion of people seeking treatment for 
cannabis use disorders has risen in all world regions apart from Africa.8 Cannabis is now the 
primary drug cited by first-time clients presenting at addiction services across Europe, 
increasing by 76% in the last decade.9 Daily use of high-THC cannabis is associated with a 
five-fold increased risk of psychosis.10 Despite the substantial and increasing demand for 
treatment there are no pharmacotherapies recommended for the treatment of cannabis use 
disorders.11  
 
Cannabidiol (CBD) is another cannabinoid found in many cannabis products4. CBD has 
minimal direct action at cannabinoid receptors but it has a broad pharmacology including 
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inhibiting the hydrolysis and reuptake of endocannabinoids12 and negative allosteric 
modulation of cannabinoid receptors13. CBD has generated significant interest due to its 
potential medicinal uses14 and ability to interact with the effects of THC.15 CBD has shown 
therapeutic effects in human and preclinical models of addiction by reducing the impact of 
drug-related cues in attentional bias16,17 cue-induced craving18 and cue-induced 
reinstatement19 paradigms. Collectively, these studies suggest that CBD may have potential 
for treating a range of substance use disorders including cannabis16, opioids18,19 and 
tobacco.17,20 A meta-analysis of randomised clinical trials found that CBD was safe and well 
tolerated with few adverse effects, but interactions with other medications should be 
monitored carefully as CBD can inhibit cytochrome P450 enzymes.21 
 
To date, no randomised trials have investigated CBD as a potential treatment for cannabis use 
disorder. Open-label case studies have reported that use of CBD products were associated 
with reduced cannabis withdrawal symptoms during cannabis abstinence.22,23 A 10-week 
open-label trial found that CBD administration was associated with improvements in  
psychological wellbeing and cognition in regular cannabis users who were not engaged in a 
cessation attempt.24 Nabiximols (a combination of THC and CBD at 1:1 ratio) has been found 
to reduce cannabis withdrawal symptoms and/or cannabis use in some randomised double-
blind placebo-controlled trials.25-27 However, the causal role of CBD in these studies is 
unclear because they either used an open-label design22-24 or co-administered THC with 
CBD.25-27 
 
Studies in human28 and rat29 models of anxiety have reported inverted-U shaped dose-
response effects of CBD. This highlights the importance of conducting an initial dose-finding 
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trial when investigating a novel indication for CBD. Trials testing a single dose against 
placebo may fail to select the most effective dose for that indication.  Therefore, in this study 
we conducted a Phase IIa trial to identify potentially effective doses and eliminate ineffective 
doses using an adaptive Bayesian design. Bayesian methods are advantageous for adaptive 
clinical trials due to their efficiency, flexibility and ability to make use of all available 
evidence in a formal and principled way. As a result, they can reduce the amount of resources 
and participant burden required when conducting clinical trials. Furthermore, Bayesian 
analyses provide direct probabilistic measures of the likelihood of a hypothesis (i.e. that a 
treatment is more effective than placebo), given the evidence provided by the data. As such 
they provide results that can be more clinically meaningful than frequentist analyses, which 
test of the likelihood of the data given the null hypothesis (i.e. that a treatment does not differ 
from placebo). We selected a dose range informed by previous clinical trials of oral CBD30,31 
of 200mg, 400mg and 800mg daily for four weeks. Our primary objective was to identify 
which (if any) dose of CBD was most effective at reducing cannabis use compared to 
placebo. 
 
Methods 
Study design and participants 
We conducted a Phase IIa, randomised, double-blind, placebo-controlled, single-site, parallel 
group clinical trial to investigate CBD as a pharmacological treatment for cannabis use 
disorder. The trial was prospectively registered before data collection began: 
https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000361-36/GB and 
https://clinicaltrials.gov/ct2/show/results/NCT02044809 The trial was approved by the UK 
Health Research Authority (13/EE/0303) and the UK Medicines and Healthcare Regulatory 
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Agency (20363/0325/001-0001). It was conducted according to Good Clinical Practice 
(GCP) and reported according to the CONSORT checklist (appendix pp 1-3).  
 
Following telephone screening and a screening visit to determine eligibility, participants 
engaged in a cannabis cessation attempt scheduled to begin at their baseline visit (week 0). At 
the end of their baseline visit they were randomised to parallel treatment arms receiving 
either CBD (200mg, 400mg, 800mg) or placebo. Participants attended site visits weekly 
during treatment (weeks 1-4). Follow up occurred at weeks 6 (site visit), 8 (telephone), 12 
(site visit) and 16 (site visit), 20 (telephone) and 24 (telephone). 
 
Participants were recruited through advertisements on websites, forums and flyers in the local 
community. We initially intended to restrict eligibility to those aged 16-26 with vital signs in 
normal limits, but removed these criteria to increase the generalizability of our findings to a 
wider population who might stand to benefit from this treatment. Inclusion criteria were age 
16-60 years, meeting DSM-5 criteria for a cannabis use disorder (at least moderate severity), 
to express a desire to stop using cannabis and intending to do so in the next month based on 
an adapted Motivation To Stop Scale.32 Participants were additionally required to report ≥1 
failed quit attempt for their cannabis use, to report co-administering their cannabis together 
with tobacco, which is the most common method of using cannabis in Europe33, to provide a 
urine sample positive for THC-COOH (Urine Cup 10A: methamphetamine, cocaine, THC, 
benzodiazepines, tricyclic antidepressants, barbituates, phencyclidine, amphetamines, 
morphine, methadone; Alere Toxicology, Abingdon, UK), and capacity to give informed 
consent as defined by GCP guidelines. 
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Females of childbearing potential were required to have a negative pregnancy test within 
seven days of starting treatment. Additional inclusion criteria for females of childbearing 
potential and all males were to use an effective method of contraception including oral, 
injected or implanted hormonal methods of contraception; placement of an intrauterine 
system or device, a barrier method of contraception, or true abstinence from the time consent 
was signed until six weeks after treatment discontinuation.  
 
Exclusion criteria were current breastfeeding or pregnancy, allergies to CBD, 
microcrystalline cellulose or gelatin, prescribed psychotropic drug use at screening 
assessments or during treatment weeks, use of other illicit drugs more than twice a month at 
screening, evidence of inaccurate self-reported drug use due to a positive urine test for a drug 
that was not reported during screening assessment, current or prior self-reported diagnosis of 
a psychotic disorder, any physical health problem deemed clinically significant by the 
investigator team, and not speaking English (due to verbal assessments). All data were 
collected at the Clinical Psychopharmacology Unit, UCL, UK. 
 
Procedures 
Synthetic CBD (99.9% purity) was obtained from STI Pharmaceuticals (Brentwood, UK) and 
manufactured by Nova Laboratories (Leicester, UK). Identical size 2 gelatin capsules 
contained microcrystalline cellulose filler and CBD (0mg, 50mg, 100mg, or 200mg).  
Participants were instructed to take two capsules twice daily to achieve daily doses of 
placebo, 200mg, 400mg and 800mg respectively. The bioavailability of oral CBD is 
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increased by food, and twice-daily administration is recommended on the basis of 
pharmacokinetic and safety data.34 Participants received scheduled text messages twice daily 
reminding them to take their medication, spaced 12 hours apart. Dosette boxes were provided 
for each week of treatment to aid compliance. Compliance was assessed by self-report at 
weekly assessments as well as return of capsules. If participants failed to show adequate 
compliance on any treatment week (either ≥ 30% capsules returned, or ≥ 30% self-reported 
doses missed), or if they failed to attend a site visit within 2 days of the scheduled 
appointment during treatment, or if any concomitant psychotropic medication was taken 
during treatment, they were not provided with additional medication for the duration of the 
trial but continued all other aspects of the protocol.  
 
All participants received a brief psychological intervention of motivational interviewing.35 
Motivational interviewing is widely used in healthcare settings and has been found to reduce 
cannabis use in randomised trials of cannabis use disorder.36 Six 30 minute sessions of 
motivational interviewing were delivered by trained psychologists at the screening visit, 
baseline visit, and treatment weeks 1-4. During the first motivational interviewing session, a 
target quit date was planned to coincide with the baseline visit. All sessions were audio 
recorded for clinical supervision. Training and supervision were provided by a lead clinical 
psychologist based in specialist National Health Service drug services throughout the 
duration of the trial. 
 
Outcomes 
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Primary outcomes were cannabis use, as measured in urine (THC-COOH:creatinine 
concentrations) and by self-report (days per week abstinent from cannabis). These were the 
two variables that were most strongly associated with cannabis use disorder severity in a 
study testing 15 different biological and self-report measures of cannabis use.37 Urine 
samples were collected at site visits using temperature monitored cups to ensure compliance 
(Galle pot, Synergy Health, Abergavenny, UK). They were stored in 10ml polypropylene 
tubes at -80°C prior to analysis using Liquid Chromotography-Tandem Mass Spectrometry 
by ABS Laboratories (Hertford, UK) with a lower limit of THC-COOH quantification of 1 
ng/ml. Self-reported days abstinent from cannabis were assessed weekly using the Timeline 
Follow-back method.38 The primary endpoint was a reduction in urinary THC-
COOH:creatinine concentrations and/or increased days per week abstinent from cannabis for 
CBD versus placebo during treatment, evidenced by posterior probabilities exceeding Pr = 
0.9. All primary endpoint data were double-entered independently by two researchers and 
were 100% verified against source data by an independent clinical trial monitor. Reductions 
in cannabis use up to the final follow up were analysed as a secondary endpoint. 
 
For secondary outcomes, we recorded the total score of the Cannabis Withdrawal Scale39, 
tobacco use assessed in urine (cotinine:creatinine concentration, lower limit of cotinine 
quantification 1 ng/ml; ABS Laboratories) and by self-report (number of cigarettes smoked 
using the Timeline Follow-back method).38 Alcohol consumption was recorded using a 
Timeline Follow-back38 of each beverage consumed and its alcohol by volume, which was 
converted to the number of standard UK alcohol units (8g alcohol). Sleep quality was 
recorded using the total score on the Pittsburgh Sleep Quality Index.40 Depression and 
anxiety were recorded using total scores on the Beck Depression Inventory41 and Beck 
Anxiety Inventory.42 Secondary endpoints were reduced cannabis withdrawal symptoms, 
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cigarette and alcohol consumption, urinary cotinine concentrations, depression and anxiety 
symptoms, and improved sleep quality, assessed (i) during treatment weeks, (ii) up to the 
final follow up. Additional secondary outcomes included cognitive, biological and 
physiological measures which will be reported elsewhere.  
 
Blood samples were collected at site visits, which were arranged at a time that was most 
convenient for each participant. Blood samples were drawn into a 6ml lithium heparin 
vacutainer and centrifuged immediately at 2800 RPM for 5 minutes. Plasma samples were 
stored in 2ml cryotubes at -80°C prior to analysis using Gas Chromotography-Mass 
Spectrometry (ABS Laboratories) with a lower limit of quantification of 0.1 ng/ml.  
 
Participants were asked about possible adverse events at each assessment from week 1 to 
week 16. Adverse events were categorized as mild (does not interfere with the participant’s 
daily routine and does not require intervention; it causes slight discomfort), moderate 
(interferes with some aspects of daily routine, or requires intervention, but is not damaging to 
health; it causes moderate discomfort) or severe (results in alteration, discomfort or disability 
which is clearly damaging to health). All adverse events were verified with a medical 
supervisor and an independent trial monitor throughout the trial on an ongoing basis. 
 
As no previous trials investigating CBD as a treatment for cannabis use disorder were available, 
our effect size estimates were informed by a pilot study testing the effects of one-week’s CBD 
treatment on cigarette consumption in tobacco smokers who intended to quit.20 On the basis of 
these data, we estimated that a sample size of n=12 per group would provide 80% power to 
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detect a similar effect of CBD in this study (d=1.21). Due to uncertainty in these estimates, we 
planned analyses at n=12 (interim analysis) and n=24 per group (final analysis) in a two-stage 
adaptive design. 
 
Randomisation and masking 
The randomisation sequence was generated by the trial statistician using block randomisation 
(R command: ‘blockrand’) with a block size equivalent to the number of treatment arms in the 
randomisation code. The randomisation code was held by the emergency un-blinding service 
(www.sealedenvelope.com) and the drug manufacturer for labelling prior to shipping to the 
trial site. Medication packages were labelled by the manufacturer and sent to the trial site with 
anonymous participant numbers. All investigators and participants remained blinded 
throughout the duration of the trial. Only blinded investigators enrolled participants, assigned 
participants to interventions, conducted assessments and entered data. Unblinding did not occur 
until after the database had been locked by the trial statistician. 
 
Statistical analysis 
All analyses were intention-to-treat. Missing data were handled using (Bayesian) multiple 
imputation under the assumption of Missing at Random. The missing outcomes are 
automatically simulated from the Bayesian procedure, in accordance with the modelling and 
distributional assumptions. In order to test our primary endpoint, THC-COOH/creatinine 
concentrations and days per week abstinent from cannabis were analysed during treatment 
weeks 1-4. We ran a Bayesian model for each dose of CBD compared to placebo to compute 
the predictive distribution of the outcome given the evidence that had become available up to 
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that point. Based on these joint posterior distributions (obtained using Markov Chain Monte 
Carlo algorithms, with model convergence assessed using the Gelman-Rubin Statistic) we 
computed the probability that each dose of CBD was the Most Effective Dose (MED) 
compared to placebo. If this probability was below a pre-specified lower threshold of Pr = 0.1, 
the dose was dropped. Similarly, if a dose exceeding a pre-specified upper threshold Pr = 0.9, 
then it was considered the MED.43 All analyses included time as a fixed effect (treatment weeks 
1-4) and were adjusted for baseline scores at week 0. Participant was fitted as a random 
intercept. For continuous, positive and skewed outcomes (e.g. THC-COOH:creatinine 
concentrations), generalised linear regression models were used assuming a Gamma 
distribution. Logistic regression models were used for binomial count outcomes (e.g. the 
number of days abstinent from cannabis in a week). Post hoc sensitivity analyses were 
conducted adding age and sex to primary endpoint models. Cannabis use (urinary THC-
COOH:creatinine, days per week abstinent) were analysed up to the final follow up as a 
secondary endpoint. Secondary outcomes were analysed separately for treatment week data 
only (weeks 1-4) and for all data (all treatment week and follow up data combined) as additional 
secondary endpoints. Models were selected assuming Gamma, Binomial or Poisson 
distributions as appropriate. Absolute differences between CBD and placebo were used to 
estimate treatment effects for all primary and secondary endpoints. These were obtained from 
statistical models including fixed effects of time, adjusted for baseline scores at week 0, and 
with a random intercept of participant. Summary statistics stratified by treatment group and 
time point were obtained from raw data. 
 
Role of the funding source 
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The UK Medical Research Council is a public-funded research council. As part of their 
Developmental Pathway Funding Scheme, the Medical Research Council panel provide expert 
guidance on clinical trial design. The funder played no role in the collection, analysis or 
interpretation of data, the writing of the report, or the decision to submit for publication. 
 
Results 
A total of 82 participants were randomised across both stages of the trial (Figure 1, Table 1). 
Across the trial, 94% of participants completed treatment as evidenced by medication 
compliance of at least 70% at each treatment week (for both self-report and returned 
medication) and attending all treatment week visits within two days of the scheduled 
appointment. Comparisons at both the interim analysis (appendix p4) and the final analysis 
(appendix p5) stages of the adaptive trial showed that CBD and placebo groups were similar 
for demographics and drug use at baseline.  
 
Between 28th May 2014 and 12th August 2015, 48 participants were randomised to placebo, 
200mg CBD, 400mg CBD and 800mg CBD (1:1:1:1). At interim analysis, CBD was more 
effective than placebo at reducing cannabis use at doses of 400mg and 800mg but not at 
200mg. For urinary THC-COOH/creatinine, both 400mg and 800mg CBD exceeded the 
primary endpoint criteria of Pr=0.9 (Pr(200mg=MED │Data)=0.4191; Pr(400mg=MED │Data)=0.9827; 
Pr(800mg=MED │Data)=0.9488). For days per week abstinent from cannabis, the 400mg CBD arm 
exceeded primary endpoint criteria of Pr=0.9, while the 200mg CBD group exceeded the 
lower threshold criteria (Pr=0.1) indicating that it should be dropped (Pr(200mg=MED 
│Data)=0.0082; Pr(400mg=MED │Data)=0.9354;  Pr(800mg=MED │Data)=0.8660), appendix p6. Therefore, 
15 
 
the 200mg CBD arm was eliminated from the trial and no further participants were 
randomised to this arm. Post hoc sensitivity analyses including age and sex did not change the 
pattern of results. 
 
Between 24th May 2016 and 12th January 2017 an additional 34 participants were randomised 
to the remaining arms of placebo, 400mg CBD and 800mg CBD (1:1:1). At final analysis, 
both 400mg CBD and 800mg CBD exceeded the primary endpoint criteria of Pr=0.9 for both 
primary outcomes: urinary THC-COOH:creatinine (Pr(400mg=MED │Data=0.9995;  Pr(800mg=MED 
│Data=0.9965), days per week abstinent from cannabis (Pr(400mg=MED │Data=0.9966; Pr(800mg=MED 
│Data=0.9247), Figure 2, Table 2. Compared to placebo, 400mg CBD decreased THC-
COOH:creatinine concentrations by -94.21 ng/ml (95% Interval Estimate= -161.83, -35.56) 
and increased abstinence from cannabis by 0.48 days per week (95% Interval Estimate=0.15, 
0.82). Compared to placebo, 800mg CBD decreased THC-COOH:creatinine concentrations 
by -72.02 ng/ml (95% Interval Estimate= -135.47, -19.52) and increased abstinence from 
cannabis by 0.27 days per week (95% Interval Estimate= -0.09, 0.64). Post hoc sensitivity 
analyses including age and sex did not change the pattern of results. 
 
At final analysis, secondary endpoints were analysed for 400mg CBD versus placebo and 
800mg CBD versus placebo (Table 3, appendix pp 7-15). Analysis of cannabis use up to the 
final follow up showed that 400g CBD reduced urinary THC-COOH:creatinine by -29.18 
ng/ml (95% Interval Estimate= -52.08, -7.25) and increased abstinence from cannabis by 0.03 
(95% Interval Estimate= 0.00, 0.07) days per week compared to placebo. However, the 
800mg CBD group was similar to placebo up to the final follow up, with an estimate of -
13.20 ng/ml (95% Interval Estimate= -37.58, 12.10) for urinary THC-COOH:creatinine and -
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0.02 (95% Interval Estimate= -0.06, 0.03) days per week abstinent from cannabis. Secondary 
outcomes were mixed, but some findings were consistent across analyses of treatment and 
follow up. Compared to placebo, 400mg CBD decreased the number of cigarettes smoked per 
week by -5.04 (95% Interval Estimate= -6.57, -3.47) during treatment and by -1.32 (95% 
Interval Estimate= -1.89, -0.60) up to the final follow up. However, compared to placebo, 
400mg CBD increased Pittsburgh Sleep Quality Index scores by 0.84 (95% Interval 
Estimate= 0.15, 1.57) during treatment and by 0.55 (95% Interval Estimate= 0.21, 0.92) up to 
the final follow up, indicating poorer sleep quality following CBD. Compared to placebo, 
800mg CBD reduced Cannabis Withdrawal Scale scores by -1.26 (95% Interval Estimate= -
2.13, -0.39) during treatment and by -2.50 (95% Interval Estimate= -3.08, -1.93) up to the 
final follow up, indicating a reduction in cannabis withdrawal symptoms following CBD. 
Compared to placebo, 800mg CBD reduced Beck Anxiety Inventory scores by -1.29 (95% 
Interval Estimate= -1.97, -0.62) during treatment and by -0.52 (95% Interval Estimate= -0.82, 
-0.27) up to the final follow up, indicating a reduction in anxiety symptoms following CBD. 
 
There were dose-response increases in plasma CBD concentrations during treatment (Table 
4). Compared to placebo, 200mg CBD increased plasma CBD concentrations by 9.37 ng/ml 
(95% Interval Estimate=5.80, 14.66), 400mg CBD increased plasma CBD concentrations by 
29.90 ng/ml (95% Interval Estimate=19.62, 49.44) and 800mg CBD increased plasma CBD 
concentrations by 46.30 ng/ml (95% Interval Estimate=33.90, 63.13). 
 
In the placebo arm (n=23) there were 65 mild adverse events and 9 moderate adverse events. 
In the 200mg CBD arm (n=12) there were 42 mild adverse events and 4 moderate adverse 
events. In the 400mg CBD arm (n=24) there were 96 mild adverse events and 8 moderate 
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adverse events. In the 800mg CBD arm (n=23) there were 78 mild adverse events and 8 
moderate adverse events. The number of mild adverse events did differ between placebo and 
200mg CBD (Relative Risk=1.24, 95% Interval Estimate=0.73, 2.09), 400mg CBD (Relative 
Risk=1.39, 95% Interval Estimate=0.91, 2.14), or 800mg CBD (Relative Risk=1.19, 95% 
Interval Estimate=0.77, 1.86), Supplementary Table S12. The number of moderate adverse 
events did not differ between placebo and 200mg CBD (Relative Risk=0.85, 95% Interval 
Estimate=0.26, 2.58), 400mg CBD (Relative Risk=0.84, 95% Interval Estimate=0.35, 2.24), 
or 800mg CBD (Relative Risk=0.89, 95% Interval Estimate=0.40, 2.45), Supplementary 
Table S13. There were no severe adverse events. 
 
The final follow-up assessment was conducted on 5th June 2017. After successfully achieving 
primary endpoint criteria, the phase IIa dose finding trial was stopped. Due to lack of funding 
a subsequent phase IIb stage (efficacy of most effective dose) was not initiated and the trial 
ended on 30th May 2018.  
 
Discussion 
In the first randomised clinical trial of CBD for the treatment of cannabis use disorder, we 
used an adaptive Bayesian design to establish which (if any) dose of CBD was more effective 
than placebo at reducing cannabis use. We eliminated 200mg CBD at an early stage and 
continued randomising to 400mg CBD, 800mg CBD and placebo treatment arms. At final 
analysis of the primary endpoint, both 400mg CBD and 800mg CBD were more effective 
than placebo at reducing cannabis use. These treatment effects were found over and above a 
brief psychological intervention typically delivered in drug treatment settings. 
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All participants in this trial met a DSM-5 diagnosis of cannabis use disorder, with 96% in the 
severe range. They expressed a desire to quit using cannabis in the next month, smoked 
tobacco with their cannabis, and had failed to quit cannabis use on at least one previous 
cessation attempt. This is an important population for which there is substantial and rising 
need for treatment and for whom no pharmacotherapies are recommended at present.11  The 
four-week treatment was completed by 94% of participants, as evidenced by self-report and 
behavioural compliance data of at least 70%, and attending all weekly treatment visits within 
2 days of scheduled appointments. CBD did not differ from placebo in the number of mild or 
moderate adverse events at 200mg, 400mg or 800mg. There were no severe adverse events, 
and no participants dropped out due to treatment. The excellent safety and tolerability data 
and exceptionally high retention rates in our trial suggest that these doses of CBD offer a safe 
and acceptable treatment for this population.  
 
To our knowledge, this is the first adaptive Bayesian dose-finding trial of CBD for a new 
medical indication. The primary objective of this Phase IIa trial was to establish which (if 
any) dose of CBD was more effective than placebo at reducing cannabis use. Both 400mg 
CBD and 800mg CBD exceeded primary endpoint criteria (Pr = 0.9) for reducing cannabis 
use during treatment, with converging evidence from biological and self-report primary 
outcomes. Our estimates showed that 400mg CBD decreased THC-COOH:creatinine 
concentrations by -94.21 ng/ml (95% Interval Estimate= -161.83, -35.56) and increased 
abstinence from cannabis by 0.48 days per week (95% Interval Estimate=0.15, 0.82), while 
800mg CBD decreased THC-COOH:creatinine concentrations by -72.02 ng/ml (95% Interval 
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Estimate= -135.47, -19.52) and increased abstinence from cannabis by 0.27 days per week 
(95% Interval Estimate= -0.09, 0.64).  
 
 
The effects of the doses tested are suggestive of an inverted-U dose response curve. The 
200mg arm was eliminated as an ineffective dose, and there was some indication that 400mg 
CBD was marginally more effective than 800mg CBD. Secondary endpoints showed that the 
reductions in cannabis were maintained up to the final follow up in the 400mg CBD arm but 
not the 800mg CBD arm. From a treatment perspective, our findings indicate that doses 
ranging from 400mg to 800mg CBD have the potential to reduce cannabis use in clinical 
settings, and it is unlikely that additional benefit would be gained from doses exceeding 
800mg CBD. It is important to be aware that this dose range (400mg to 800mg CBD) is 
considerably higher than those in CBD products widely available without a prescription (e.g. 
25mg per day).14  These products lack quality assurance and should not be used for medicinal 
purposes. 
 
There were mixed results for other secondary endpoints, but some findings were consistent 
across treatment weeks and follow up. Compared to placebo, 400mg CBD decreased the 
number of cigarettes smoked in line with previous studies of CBD in tobacco smokers.17,20 
However, sleep quality was lower in the 400mg CBD group compared to placebo, which may 
be interpreted in the context of greater reductions in cannabis use in this group. Compared to 
placebo, 800mg CBD reduced cannabis withdrawal symptoms, consistent with previous case 
20 
 
reports22,23 and reduced anxiety symptoms in line with experimental studies in humans28 and 
rats.29 
 
Key strengths of this study include its novel indication for which there is substantial clinical 
need, and its adaptive Bayesian dose-finding design. This design enabled us to test a range of 
doses in an efficient manner, which would have required considerably greater resources and 
participant burden when using a typical trial design. In terms of limitations, this Phase IIa 
dose-finding trial was not designed to estimate efficacy. Further evidence is needed to 
improve the precision of the estimates obtained in this study. Although there was strong 
evidence for dose-response effects of CBD on plasma CBD concentrations, factors such as 
food consumption could have contributed to variation in the bioavailability of CBD. This trial 
used a four-week treatment period, consistent with a previous clinical trial for psychosis.30 
Further studies  are needed to investigate the extent to which these findings translate to 
different durations of treatment. Additional research is needed to investigate if CBD reduces 
cannabis use independently, or through mechanisms shared with other mental health 
symptoms such as anxiety. 
 
In conclusion, our trial provides the first causal evidence supporting CBD as a treatment for 
cannabis use disorders. These findings are important in light of major policy changes 
surrounding the production and sale of cannabis products, increases in the number of people 
entering treatment for cannabis use disorders worldwide8,9 and the absence of recommended 
pharmacotherapies at present.11 
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Figure 1: CONSORT diagram showing enrolment, allocation and analysis at interim and 
final stages of the adaptive trial 
Assessed for eligibility (n=107)
Excluded (n=59)
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¨ Received allocated intervention 
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medication adherence)
Allocated to 400mg (n=12)
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Figure 2: Primary endpoint: final analysis. Each cloud of points represents the expected 
value of the primary outcome for participants randomised to CBD or placebo, simulated 
from the joint posterior distribution of treatment arms. Both 400mg and 800mg CBD exceed 
the upper threshold (Pr=0.9) for primary endpoint criteria, showing reduced THC-
COOH:creatinine concentrations (left panel) and increased days per week abstinent from 
cannabis (right panel) compared to placebo. 
27 
 
Table 1: Characteristics of all participants included in both interim and final analysis stages 
of the trial. Data show frequencies, percentages, means and 95% Interval Estimates for the 
placebo (n=23), 200mg CBD (n=12), 400mg CBD (n=24) and 800mg CBD (n=23) groups 
 Placebo 200mg CBD 400mg CBD 800mg CBD 
Age 24.87 
(18.55, 43.35) 
27.33  
(19. 28, 39.08) 
26.58 
(19.15, 41.25) 
27.43 
(19.00, 36.90) 
 
Sex (% male, male/female) 73.91%, 17/6 75.00%, 9/3 70.83%, 17/7 69.57%, 16/7 
 
DSM-5 CUD symptoms at 
screening assessment  
8.61 
(7.63, 9.58) 
 
8.67  
(7.63, 9.70) 
9.00 
(8.29, 9.71) 
8.48 
(7.39, 9.57) 
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Table 2: Primary endpoint data. Means (95% Interval Estimates) stratified by group and time point at final analysis of placebo (n=23), 
400mg CBD (n=24) and 800mg CBD (n=23) treatment arms 
 
  Placebo  400mg  800mg 
  
Urinary THC-COOH: 
creatinine (ng/ml) 
Days abstinent 
from cannabis 
 
Urinary THC-COOH: 
creatinine (ng/ml) 
 
Days abstinent 
from cannabis 
 
Urinary THC-COOH: 
creatinine (ng/ml) 
Days abstinent 
from cannabis 
Baseline  
343.09 
(188.41, 497.78) 
1.17 
(0.48, 1.87) 
 
521.00 
(316.55, 725.44) 
0.79 
(0.34, 1.24) 
 
315.31 
(150.00, 480.61) 
1.65 
(0.68, 2.62) 
Week 1  
202.99 
(68.59, 337.38) 
4.17 
(3.29, 5.05) 
 
267.60 
(71.61, 463.60) 
4.25 
(3.40, 5.10) 
 
142.27 
(70.65, 213.90) 
4.04 
(3.07, 5.01) 
Week 2  
187.53 
(89.46, 285.60) 
3.83 
(2.77, 4.88) 
 
227.17 
(77.62, 376.72) 
4.17 
(3.26, 5.07) 
 
98.04 
(53.89, 142.20) 
4.43 
(3.55, 5.32) 
Week 3  
185.53 
(88.22, 282.84) 
4.36 
(3.26, 5.46) 
 
272.31 
(62.70, 481.92) 
4.67 
(3.75, 5.58) 
 
125.73 
(60.51, 190.94) 
4.52 
(3.63, 5.41) 
Week 4  
195.00 
(92.08, 297.92) 
4.14 
(3.20, 5.08) 
 
251.24 
(95.38, 407.11) 
4.38 
(3.39, 5.36) 
 
144.07 
(48.53, 239.62) 
4.91 
(4.05, 5.78) 
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Table 3: Final analysis of primary and secondary endpoints. Data show the absolute difference (95% Interval Estimate) between 400mg 
CBD (n=24) and placebo (n=23) and between 800mg (n=23) and placebo (n=23). Separate analyses are presented for treatment weeks only 
and up to the final follow up 
 
a Primary endpoint 
 
 
 
 
 
 
 
  Treatment weeks  Up to final follow up 
  400mg vs Placebo  800mg vs Placebo  400mg vs Placebo  800mg vs Placebo 
THC-COOH:creatinine (ng/ml)  -94.21a (-161.83, -35.56)  -72.02a (-135.47, -19.52)  -29.18 (-52.08, -7.25)  -13.20 (-37.58, 12.10) 
Days abstinent  0.48a (0.15, 0.82)  0.27a (-0.09, 0.64)  0.03 (0.00, 0.07)  -0.02 (-0.06, 0.03) 
Cannabis Withdrawal Scale  -0.34 (-1.14, 0.50)  -1.26 (-2.13, -0.39)  -1.32 (-1.89, -0.60)  -2.50 (-3.08, -1.93) 
Urinary cotinine:creatinine (ng/nl)  -72.31 (-194.35, 36.57)  -36.08 (-163.46, 104.28)  -66.52 (-157.06, 13.10)  -56.60 (-145.36, 35.19) 
Cigarettes smoked  -5.04 (-6.57, -3.47)  8.66 (6.89, 10.26)  -1.32 (-1.89, -0.60)  -2.50 (-3.08, -1.93) 
Alcohol units consumed  15.32 (-3.60, 49.27)  -8.49 (-17.27, 0.44)  0.86 (-2.82, 3.84)  -1.50 (-4.83, 1.04) 
Pittsburgh Sleep Quality Index  0.84 (0.15, 1.57)  0.16 (-0.57, 0.81)  0.55 (0.21, 0.92)  0.46 (0.08, 0.82) 
Beck Depression Inventory  0.34 (-0.47, 1.17)  0.14 (-0.70, 1.00)  -0.48 (-0.76, -0.21)  -0.21 (-0.49, 0.07) 
Beck Anxiety Inventory  1.41 (0.65, 2.17)  -1.29 (-1.97, -0.62)  0.01 (-0.25, 0.34)  -0.52 (-0.82, -0.27) 
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Table 4: Mean (95% Interval Estimates) plasma concentrations of CBD (ng/ml) stratified by group 
and time point in the Placebo (n=23), 200mg (n=12), 400mg (n=24) and 800mg (n=23) treatment 
arms 
 
Placebo  200mg CBD 400mg CBD 800mg CBD 
Week 0 
0.12  
(-0.01, 0.24)  
0.02  
(-0.01, 0.06)  
0.15  
(-0.06, 0.36)  
0.02  
(-0.02, 0.07)  
Week 2 
0.06  
(-0.03, 0.15)  
10.28  
(4.20, 16.36)  
40.42  
(19.12, 61.72)  
59.31  
(17.95, 100.67)  
Week 4 
0.07  
(0.00, 0.13) 
 
10.24  
(2.65, 17.83) 
 
21.63  
(11.06, 32.20) 
 
63.33  
(30.09, 96.57) 
 
Week 6 
0.09  
(-0.04, 0.21)  
0.49  
(0.32, 0.66)  
4.14  
(0.12, 8.16)  
3.91  
(2.42, 5.41)  
Week 12 
0.02  
(-0.03, 0.08)  
0.00  
(0.00, 0.00)  
0.19  
(0.06, 0.32)  
0.34  
(0.14, 0.55)  
 
 
 
 
 
 
 
 
